Literature DB >> 32430845

MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers.

Mohammed Elhendawy1, Enas A Abdul-Baki2, Sherief Abd-Elsalam3, Maha M Hagras4, Abdul-Aziz Zidan5, Amira Y Abdel-Naby4, Mona Watny4, Ibrahem Ali Elkabash6, Mohamed Labib Salem7, Mohamed Elshanshoury8, Shaimaa Soliman9, Said Abdou4.   

Abstract

MicroRNAs (miRNAs) play important roles in liver pathologies and they are potential biomarkers for diagnosis of liver diseases progression. Changes in miRNA sera expression can be used as non-invasive biomarkers for hepatocellular carcinoma (HCC). The aim of the study was to identify the miRNome profiling of HCC and its diagnostic value in distinguishing HCC from healthy individuals. Expression profiles of miRNAs in serum samples of 20 HCC patients and 10 healthy controls were detected. Whole miRNome profiling was done using next generation sequencing. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic performance of the deregulated miRNAs for discriminating HCC cases from healthy controls. MiRNA 142 was highly expressed in HCC (P value = 0.023) while miRNAs 191, 22, and 126 were higher in the controls (P value = 0.005, 0.034, 0.010 respectively). We have identified 5 novel miRNAs and they were highly expressed in HCC than controls. Analysis of ROC curve demonstrated that these deregulated miRNAs can be used as a reliable biomarker for detection of HCC with high diagnostic accuracy (AUC = 0.93). We have detected a panel of serum miRNAs that can be used as a reliable noninvasive screening biomarker of HCC. The study recommends further research to shed light on a possible role of the newly discovered novel miRNAs in HCC pathogenesis.

Entities:  

Keywords:  Egypt; Gene; HCC; Hepatitis C virus; Marker; Tumors

Mesh:

Substances:

Year:  2020        PMID: 32430845     DOI: 10.1007/s11033-020-05521-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  7 in total

1.  Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma.

Authors:  Yujia Fang; Dong Yan; Lixin Wang; Jie Zhang; Qingfang He
Journal:  J Clin Lab Anal       Date:  2022-06-06       Impact factor: 3.124

2.  Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.

Authors:  Bin Yu; Shujun Zhou; Han Liang; Qifa Ye; Yanfeng Wang
Journal:  Dig Dis Sci       Date:  2021-05-12       Impact factor: 3.487

3.  Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma.

Authors:  Wei Wang; Zhenfeng Deng; Zongrui Jin; Guolin Wu; Jilong Wang; Hai Zhu; Banghao Xu; Zhang Wen; Ya Guo
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

Review 4.  Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities.

Authors:  Abhiram Natu; Anjali Singh; Sanjay Gupta
Journal:  World J Hepatol       Date:  2021-11-27

5.  Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study.

Authors:  Zhikun Liu; Yuanpeng Liu; Wenhui Zhang; Yuan Hong; Jinwen Meng; Jianguo Wang; Shusen Zheng; Xiao Xu
Journal:  Hepatol Int       Date:  2022-03-29       Impact factor: 9.029

6.  Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma.

Authors:  Daxiang Zhou; Ling Dong; Lishan Yang; Qiang Ma; Feng Liu; Yanjie Li; Shu Xiong
Journal:  IET Syst Biol       Date:  2020-12       Impact factor: 1.615

7.  Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma: An up-to-date meta-analysis.

Authors:  Pei-Pei An; Li-Na Feng; Xiao-Xue Zhang; Qing-Long Jin
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.